Tenet Healthcare Corporation (NYSE: THC) — A Surgery-Center Compounder Hiding Inside a Hospital, Re-Rated From Falling Knife to Full Fare

Independent equity research · Research date: 2026-07-02 · Report currency: USD · Fiscal year ends December 31

This is an independent research article. The analysis that follows deliberately carries no buy/sell recommendation and no price target. The single exception is the Author’s Take block immediately below, which is a clearly labeled, subjective opinion.

⚡ Author’s Take

This block is the author’s own subjective opinion and general information only — not investment advice. Everything from the Executive Summary onward is position-free and carries no price target.

Verdict: HOLD / accumulate-on-weakness / not-a-short. A genuinely transformed, higher-quality business whose easy re-rating is behind it — own it cheaper, don’t chase it here. Conviction: medium. Fair-value zone roughly ~$180–210 (~7x forward EV/EBITDA / ~11–12x forward adjusted EPS), with materially better risk/reward on weakness below ~$165 (~6.3x EV/EBITDA) — precisely where the stock traded four weeks ago. The multiple gets genuinely full again above ~$230 (~8x EV/EBITDA, HCA-parity), which is where the sell-side price targets ($233–245) and February–May insider selling clustered.

Tenet is no longer the levered, scandal-prone hospital roll-up of the last decade. Over five years management divested ~14 mediocre hospitals for ~$5B, cut net leverage from ~4.4x to ~2.4x (earning a Moody’s upgrade to Ba2 in June 2026), and shifted the profit center to USPI, the #1 ambulatory-surgery-center operator in the country — a ~39%-margin, low-double-digit-growth business that now throws off 44% of segment EBITDA on 24% of revenue. That is a real, capital-light compounder riding the secular inpatient-to-outpatient shift, and it is the reason the stock 5-x’d off its 2022 low. I would not short it: the balance sheet is fixed, USPI is genuinely good, and the buyback still shrinks the float ~8%/year.

But two facts keep this a HOLD, not a buy-here. First, the price already embeds the good news. THC screens cheap on earnings (~11–12x forward) only because margins are at record highs — on price-to-sales it sits at the 94.6th percentile of its own ten-year history, its richest-ever. You are paying a peak-margin multiple on a revenue base whose hospital half (still 56% of EBITDA) faces a staggered policy squeeze: the ACA enhanced-subsidy expiration (~$250M 2026 EBITDA hit, worse in 2027) and OBBBA’s Medicaid state-directed-payment caps phasing in from 2028 against a ~$1.2B high-margin supplemental-Medicaid stream. Second, ~40% of the crown jewel isn’t Tenet’s — USPI’s physician partners took $960M of 2025’s $2.37B consolidated net income and ~$0.8–1.0B of cash out the door. The moat is partly rented from the very surgeons who constitute it, and consolidated FCF flatters the common holder’s real claim. Add insiders who have sold — never bought — into the entire run-up and a comp plan with no ROIC metric, and the risk/reward at $204 is symmetric at best: my scenarios frame roughly $100–120 downside (policy + a multiple de-rate; leverage and NCI amplify it) against ~$290–320 upside (continued compounding + HCA-ward re-rate), with base case ~$190–215, i.e., about spot.

Framing: re-rated, idiosyncratic (~87% stock-specific, low-beta ~0.7) quality-at-a-price — not a momentum trade, and no longer the 2022 falling knife. Flips bullish on two consecutive beat-and-raise quarters with USPI same-facility growth staying double-digit and hospital EBITDA margins holding through the first post-EPTC quarters (policy absorbed → re-rate toward HCA). Flips bearish if USPI cases decelerate for two quarters, hospital margins crack >150bp on rising uninsured mix, or leverage backs up and the buyback is cut — any of which would break the “compounding continues” story the multiple now requires. Tag: a great surgery business, half-owned by its own doctors and priced at peak margins — buy the policy fear, don’t pay full fare.

📈 Stock Price Action — Five-Year Event Map

Factual price history — no recommendation, no price target. Price moves are FACT (AZI 5-year daily series); attributed drivers are INTERPRETATION.

The arc in plain numbers. THC round-tripped from a COVID-era ~$47 (early 2021) down to a five-year low of $37.50 on Oct-21-2022, then staged one of the largest re-ratings in the S&P 500 — +443% off that low — to a five-year / all-time high of $244.80 on Mar-4-2026. It now trades at $203.72, roughly 17% below that peak, having bounced ~26% off a ~$161 local low in June 2026. The 52-week range is ~$114–$245. Today’s (2026-07-02) +8.5% move on ~2x normal volume pushed it back above its 50-/200-day EMAs (~$183 / ~$189) after two months underneath them. Factor data confirm the whole journey is ~87% idiosyncratic (R²~12% to market factors; low beta ~0.7) — a stock-specific deleveraging-and-mix-shift story, not a factor ride.

Cycle narrative. (1–2) The 2021–22 round-trip was macro: a reflation rally into a rate-shock bear market, in which THC’s then-high leverage made it a high-beta casualty down to $37.50. (3) The 2022–24 quadruple is the heart of the story — Tenet sold ~14 low-margin hospitals (~$5B proceeds, booked as ~$2.9B of one-time 2024 gains), paid down debt, and let USPI’s ~40% margins pull the blended EBITDA margin from the mid-teens toward 20%+; the market re-rated the multiple from a distressed ~4x to ~7x EV/EBITDA. (4) A ~31% drawdown on early 2025 policy jitters and a tariff/macro shock. (5–6) A fresh ~90% advance on repeated 2025 beat-and-raises to the March-2026 all-time high. (7) The ~34% policy-scare drawdown — the ACA enhanced premium tax credits (EPTC) expired at end-2025 and OBBBA’s Medicaid cuts came into focus — hit the whole hospital cohort. (8) The June–July recovery is fundamental and idiosyncratic: a clean Q1’26 beat, a raised EPS view, the Moody’s upgrade, and bullish analyst notes (TD Cowen reiterated Buy on Jun-22 while trimming its target to $233; Cantor reiterated Overweight with a $245 target on Jul-2 alongside today’s pop). This is a mean-reversion off an oversold, stock-specific washout — not a factor rotation.

1. Executive Summary

Tenet Healthcare is a Dallas-based diversified care-delivery company that has, over five years, quietly rebuilt itself from a scandal-tinged, over-levered hospital operator into a two-engine business where the smaller engine earns the profits. It reports two segments: Hospital Operations & Services (50 acute-care/specialty hospitals in eight states, plus employed physicians, outpatient sites, and the Conifer revenue-cycle-management unit) and Ambulatory Care, which is USPI (United Surgical Partners International) — the largest ambulatory-surgery-center operator in the United States, with interests in 533 ASCs and 26 surgical hospitals across 37 states. FY2025 revenue was $21.31B; company-defined segment Adjusted EBITDA was $4.57B (21.4% margin), up from ~16.8% five years ago.

The single most important fact in this memo is the segment split. USPI generated $2,026M of Adjusted EBITDA on $5,172M of revenue — a ~39% margin, ~2.5x the hospital segment’s — meaning 44% of segment profit comes from 24% of revenue. USPI’s margins have held ~39–40% while the hospital segment’s margin expanded from 12.0% (FY2023) to 15.7% (FY2025) as management divested low-margin facilities and drove acuity and throughput in what remains. This is the mix-shift-plus-margin-expansion engine that took the stock from $37.50 (October 2022) to a $244.80 all-time high (March 2026).

The balance-sheet transformation is equally real. Net debt fell from ~$14.2B (2022) to ~$10.3B (2025), net leverage from ~4.4x to ~2.4x, earning a Moody’s upgrade to Ba2 in June 2026. Share count shrank from ~106M (2020) to 86.95M (2025) via buybacks, and there is no dividend. Free cash flow (consolidated) was ~$2.5B in 2025.

There are, however, three structural catches that keep this from being a clean quality-compounder story. First, Tenet does not keep all of USPI’s profit. The ASC model is built on physician-owner joint ventures, and those minority partners captured $960M of 2025’s $2.37B consolidated net income (~40%) and ~$0.8–1.0B of cash distributions; consolidated FCF materially overstates the common holder’s claim. Second, the hospital half — still 56% of EBITDA — carries a staggered policy squeeze: the ACA EPTC expiration (a ~$250M 2026 EBITDA headwind, worse in 2027) and OBBBA’s caps on Medicaid state-directed payments and provider taxes, which phase in from 2028 against a ~$1.2B high-margin supplemental-Medicaid revenue stream. USPI’s commercial-elective book is largely insulated; the hospital book is not. Third, capital allocation and incentives are merely adequate: the buyback spent the most dollars at the highest prices, the comp plan rewards EBITDA/EPS/FCF size with no ROIC metric, and insiders have sold — never bought — into the entire five-year run-up.

Valuation is the crux. At $203.72, THC trades at ~6.8–7.0x forward EV/EBITDA and ~11–12x forward adjusted EPS — a ~2-turn discount to HCA (~8.6x) that is deserved on lower quality (ROIC ~13–15% vs. HCA’s ~20%). But on its own ten-year history the picture splits sharply: cheap on book (P/B 16th percentile) and mid-range on earnings (P/E ~45th), yet richest-ever on sales (P/S 94.6th percentile) — the unmistakable signature of a business valued at peak margins. A reverse-DCF implies the market is underwriting ~mid-single-digit forward EBITDA/FCF growth: continuation of the USPI story, not a permanent impairment. The debate is therefore whether the re-rating is done (upside must now come from earnings compounding, not multiple expansion) or whether policy will force a margin-and-multiple double-de-rate. This memo lays out both cases and the evidence that would settle them — without rendering a recommendation.

2. Business Overview

What Tenet is now. Tenet Healthcare (founded 1967, headquartered in Dallas, TX; CIK 70318) operates two reportable segments, managed by a Chief Operating Decision Maker group (the CEO and CFO) that evaluates each on Adjusted EBITDA (FACT — FY2025 10-K, Segment Note):

• Hospital Operations & Services. At 12/31/2025, subsidiaries operated 50 acute-care and specialty hospitals across eight states (down from 65 hospitals in 2020), together with ~132 outpatient facilities (urgent care, imaging centers, off-campus emergency departments, micro-hospitals), employed physician practices, and Conifer — a revenue-cycle-management and value-based-care services business. Hospital Operations produced FY2025 revenue of $16,138M and Adjusted EBITDA of $2,540M (a 15.7% margin).
• Ambulatory Care = USPI. Tenet holds ownership interests in 533 ambulatory surgery centers (401 consolidated) and 26 surgical hospitals in 37 states, performing ~2 million procedures per year, operated through joint ventures with physicians and health-system partners under management-services agreements. Ambulatory Care produced FY2025 revenue of $5,172M and Adjusted EBITDA of $2,026M (a 39.2% margin). (FACT — 10-K, Item 1 and Segment Note.)

Where the money is made. The two-segment table is the whole business in one view:

(The segment total of $4,566M includes $264M of equity in earnings of unconsolidated affiliates, mostly USPI’s non-consolidated JVs; Tenet’s press-release “consolidated Adjusted EBITDA” uses a modestly narrower definition. The segment split and margins are the load-bearing facts.)

How USPI makes money. USPI is a short-stay, high-throughput surgical business. Surgeons and health systems co-own each center alongside Tenet; Tenet contributes scale (purchasing, payer contracting, a de-novo development playbook) and management. Revenue is overwhelmingly commercial and elective — orthopedics and total-joint replacement, spine and musculoskeletal, GI, pain management, ENT, ophthalmology, urology — with cases increasingly migrating out of the hospital as CMS expands its ASC-covered-procedure list and payers steer volume to lower-cost settings. Same-facility systemwide FY2025 growth was +7.5% in revenue, but only +0.3% in cases and +7.1% in revenue-per-case (FACT) — i.e., growth is acuity- and mix-driven (higher-value procedures moving outpatient), supplemented by tuck-in M&A and de novos, not by raw case throughput.

How the hospital segment makes money. The hospital book is a mature, low-growth, margin-managed franchise. FY2025 hospital payer mix on $13,942M of net patient service revenue was managed care 69.5% ($9,696M), Medicare 15.2%, traditional Medicaid 10.9% ($1,524M), indemnity/other 4.0%, and uninsured 0.4% (FACT — 10-K payer-mix table). Including managed Medicaid, total Medicaid-related hospital revenue is ~$2.82B (~17.5% of the segment). Critically, the hospital book is ~70% commercial — better than the safety-net average — which matters for the policy analysis in and Volume is essentially flat (Q4’25: admissions +0.4%, adjusted admissions +0.9%, surgeries +0.9%, length of stay −1.2%); profit growth comes from acuity mix-up, throughput, and cost discipline, plus the arithmetic of having sold the weakest hospitals.

Conifer. Conifer provides revenue-cycle management to hospitals, health systems, and physician groups; it was 76.2%-owned at year-end 2025 (CommonSpirit held 23.8%), and Tenet bought back full ownership effective January 1, 2026. It is reported within Hospital Operations’ “Other revenues” (~$2.2B, primarily employed physician practices plus Conifer). It is a stable, capital-light services annuity, small relative to the two care-delivery engines but strategically useful (patient access, denials management).

Revenue recurrence. Neither segment is “recurring” in a subscription sense, but demand is demographic and largely non-discretionary: acute care is driven by emergencies, chronic disease, and aging; USPI’s elective surgical volume is driven by a growing, insured population choosing lower-cost settings. The business is defensive on volume but sensitive on payer mix — a recession or a coverage shock hits the mix (more uninsured/Medicaid) even when it does not hit the caseload.

3. Industry Dynamics

A two-sided industry. Tenet straddles two structurally different businesses, and the investment case depends on telling them apart.

For-profit hospitals: structurally average, capital-heavy, policy-fragile. The U.S. acute-care hospital industry is fragmented nationally but concentrated locally — patients, physicians, and commercial payers contract market-by-market, so local density, not national share, is what confers pricing power. For-profit operators (HCA, UHS, Community Health Systems, Tenet) compete against dominant not-for-profit systems that enjoy tax exemptions they do not. Roughly 40% of industry revenue comes from government payers at administered (below-commercial, often below-cost for Medicaid) rates; the commercial ~half cross-subsidizes the rest. Capital intensity is enormous (a tertiary hospital is a multi-hundred-million-dollar, multi-year build), returns are middling, and the segment is directly exposed to reimbursement and coverage policy. A Marathon capital-cycle read is instructive here in reverse: Tenet has been shrinking its hospital fleet — divesting ~14 facilities for ~$5B in 2023–24 — which is rational capital-cycle behavior (exiting a mediocre-return, capital-hungry business to redeploy into higher-return ASCs), but it does not make hospitals a good industry, only a better-managed position within an average one. Verdict: structurally below-average and policy-exposed.

Ambulatory surgery centers: structurally attractive and the entire reason to own THC. The U.S. ASC market is ~$40B and growing ~3.5–6%/year, powered by the secular inpatient-to-outpatient migration: ASCs deliver equivalent-or-better outcomes at ~40–60% lower cost per procedure, and CMS, commercial payers, and (increasingly) an inpatient-only-list phase-out beginning in 2026 all push volume in that direction. USPI is the #1 operator (~535 facilities); SCA Health/Optum (payer-owned, ~320 facilities) is #2, followed by Surgery Partners (SGRY, a levered pure-play), AmSurg, and — deliberately far behind — HCA (~124 ASCs; HCA is intentionally hospital-centric). The capital cycle here is favorable but heating up: private-equity and payer capital are flooding in, and USPI itself is a serial acquirer — the classic Marathon warning sign that high returns attract capital and eventually compress acquisition multiples and de-novo economics. Verdict: structurally attractive, secular-growth, but with intensifying competition (notably payer-owned Optum/SCA) that bears watching.

Regulation. Certificate-of-Need (CON) laws in many states restrict new beds and, in ~40% of USPI’s states, new ASCs — a genuine but slowly eroding incumbent barrier (South Carolina, for example, sunsets hospital CON on January 1, 2027). EMTALA obligates hospitals to treat emergencies regardless of ability to pay — the channel through which a rising uninsured population becomes uncompensated-care cost. Site-neutral payment policy (paying the same rate regardless of setting) is a slow-moving federal theme that would compress the inpatient premium; Tenet is relatively insulated because USPI is mostly freestanding ASC rather than hospital-outpatient-department (HOPD), and management frames CMS’s stated tilt toward lower-cost settings as a net positive for USPI.

Net industry verdict. A structurally attractive ambulatory business bolted onto a structurally average, policy-fragile hospital business. The blend is improving because Tenet is deliberately shifting weight to the good half — but the average half still produces the majority of profit and carries essentially all of the policy risk.

4. Competitive Position

Two moats of very different quality. In Greenwald’s taxonomy, Tenet’s competitive advantages must be assessed segment by segment.

Hospital segment — local economies of scale + customer captivity + CON, but shallow and policy-contingent. Within a given metro, a hospital with local density, entrenched physician relationships, and payer contracts is hard to dislodge, and CON laws raise the entry barrier. But this is the weakest durable-advantage type: it is regional (it does not travel), it fails a national share-stability test, its returns are structurally lower than USPI’s, and it is directly exposed to administered pricing and coverage policy. A 2020 expert-network interview with a former Tenet managing director (dated, treated as framework, not current data) corroborates the mechanism: hospital competition is local and service-line-specific — Tenet avoids markets where HCA is #1 in a given service line and instead positions where it can win. This is a real but narrow, policy-contingent moat — “a good local position in an average business,” not a durable franchise.

USPI — the real moat: economies of scale + physician-JV captivity. Three reinforcing mechanisms:

1. Physician-owner alignment (captivity). Surgeons hold equity in the ASC and steer their case volume to the center they co-own. Cases follow ownership — the single strongest lock-in in the model, and one a lone competitor cannot easily replicate.
2. Scale in ASC operations. As the #1 operator, USPI has advantages in supply purchasing, payer contracting, de-novo development, and health-system JV partnerships that a single-site or sub-scale ASC cannot match. Same-facility revenue-per-case up +7.1% evidences genuine pricing/mix power.
3. Health-system JV relationships and a de-novo pipeline (e.g., Baylor, Memorial Hermann) create a proprietary growth channel — partner hospitals contribute cases, referrals, and market credibility.

Pressure-testing the USPI moat. It is real and reasonably durable, but with three important caveats. (i) The physician alignment that creates captivity also caps Tenet’s economics. The partners who make the moat take ~40% of USPI’s economics ($805M of the $960M FY2025 NCI came from Ambulatory Care) — the moat is partly shared with, and rented from, the very surgeons who constitute it. (ii) Competition is intensifying. Optum/SCA is a structurally dangerous competitor: payer-owned, it can steer volume through UnitedHealthcare network design; and Surgery Partners plus PE capital compete for the same physician JVs and acquisition targets, pressuring multiples. (iii) Reimbursement risk. ASC rates are benchmarked to Medicare/commercial; an aggressive extension of site-neutral policy could narrow the inpatient-vs-outpatient spread that drives the migration.

Where THC sits on quality. Below HCA — the gold-standard integrated operator, with ~20% ROIC, superior scale, a denser Sun-Belt hospital moat, and a stronger balance sheet. But USPI is arguably the best pure ASC franchise in the country, ahead of Surgery Partners on scale, margin, and balance-sheet quality. The right mental model is “a genuinely good business (USPI) stapled to an average one (hospitals)” — blended quality dragged down by hospital cyclicality and policy exposure, lifted by USPI’s structural growth, and complicated by the fact that a large minority of the good business belongs to someone else. Verdict: a durable advantage in USPI (narrowed by shared economics and rising competition) plus a shallow, policy-contingent local advantage in hospitals — better than the peer average, well short of HCA.

5. Growth History and Forward Opportunities

Historical growth. Consolidated revenue has been essentially flat-to-modestly-up ($17.6B in 2020 → $21.3B in 2025, ~3.9% CAGR) — but the composition is the story, because divestitures shrank the hospital top line while USPI grew into it. The truer growth signal is segment Adjusted EBITDA: consolidated segment Adjusted EBITDA rose from $3,541M (2023) to $4,566M (2025), a +14% year in 2025. Underneath:

• USPI Adjusted EBITDA: $1,544M (2023) → $1,810M (2024) → $2,026M (2025) — a ~14.6%/yr CAGR, on stable ~39–40% margins and +7.5% same-facility revenue growth (well above USPI’s own 3–6% long-term algorithm).
• Hospital Adjusted EBITDA: $1,997M (2023) → $2,185M (2024) → $2,540M (2025) — a ~12.8%/yr CAGR achieved on flat-to-down revenue: this is pure margin expansion (12.0% → 15.7%), driven by divesting the weakest hospitals, acuity mix-up, and a six-quarter run of length-of-stay reduction.

Forward growth architecture. Management’s stated engine is USPI plus disciplined M&A:

• USPI same-facility algorithm: +3–6% organic revenue growth, which has been running above range (+7.5% in 2025) on acuity mix-up. The inpatient-only-list phase-out beginning 2026 is framed as a multi-year, gradual tailwind (2026 focus: high-acuity spine and urology moving outpatient), on top of >150 ASC robotics programs and double-digit same-store total-joint-replacement volume growth.
• USPI M&A + de novo: ~$250M/yr. In 2025 Tenet deployed ~$350M and added 35 facilities; in Q1’26 alone it invested $125M and added 7 ASCs plus 3 de novos — roughly half the annual budget in one quarter. The network is now ~570 centers. Caution: this means reported USPI EBITDA growth is a hybrid of genuine organic (3–6%) plus a persistent, capital-consuming roll-up — not all “same-store.”
• Hospital segment: a five-year-running high-acuity playbook (transfer centers, trauma/ER expansion, new surgical programs) plus throughput/LOS reduction to create capacity without heavy capex; one greenfield opened in 2025 (the 54-bed Florida Coast Medical Center). Volume growth will remain low-single-digit; the lever is margin, and the runway on margin is narrower than it was.

Guidance context (FY2026). Revenue $21.5–22.3B; consolidated Adjusted EBITDA $4.485–4.785B ($4.635B midpoint, ~+1.5% over 2025 at the midpoint but ~+10% “core” ex-EPTC and ex-2025-one-timers per management); USPI Adjusted EBITDA $2.13–2.23B; hospital Adjusted EBITDA $2.355–2.555B. Same-hospital adjusted admissions +1–2%; USPI same-facility revenue +3–6%. Q1’26 delivered a clean beat (revenue +10.7%, adjusted EPS $4.82 vs. ~$4.16 consensus), which management deliberately did not flow through to the EBITDA guide.

Verdict: high-quality growth in USPI (capital-efficient, mix-driven, high-return), lower-quality growth in hospitals (margin-led, one-time-ish, with a shorter runway) — and a reported consolidated growth rate flattered by a serial ASC roll-up and, in 2026, by a cost/AI program whose durability into 2027+ is unproven. Genuinely good, but not the unqualified secular compounder the bulls describe.

6. Financial Quality

Margins and their trajectory. The defining financial fact is margin expansion: consolidated segment Adjusted EBITDA margin rose from ~16.8% (2021) to 21.4% (2025), and the quarterly path has kept climbing (18.9% in Q1’25 to 21.6% in Q1’26). This is real and mix-driven — USPI’s ~39% margins are a growing share of the whole, and the hospital segment re-margined from 12.0% to 15.7%. But it is precisely because margins are at record highs that the stock screens cheap on earnings and expensive on sales: you are capitalizing peak profitability.

Cash flow. FY2025 operating cash flow was $3,540M against net income of $2,367M — clean conversion, no net-income-vs-cash divergence red flag. Capex was ~$1,010M (~4.7% of revenue), yielding consolidated free cash flow of ~$2,530M (~$28/share). But the headline FCF materially overstates the equity holder’s claim (see NCI below); management’s own “Adjusted FCF less NCI” was ~$1,842M in 2025, guided to $1.6–1.83B in 2026 — the figure that actually accrues to Tenet shareholders.

Returns on capital. ROIC (ROIC.ai) was ~13.25% in 2025, up from ~9% in 2021–23 — above the ~8–9% cost of capital, but well below HCA’s ~20%. Reported ROE (~38%) and book-value ratios are not usable: Tenet carries ~$11.2B of goodwill and ~$1.35B of intangibles against a thin equity base, producing negative tangible book value (~−$40/share) — an artifact of goodwill-funded USPI acquisitions and years of buybacks, not distress. P/B is not a meaningful metric here (and swung from negative to ~3.7x as equity recovered); the AZI P/B percentile (16th) reflects that recovery, not cheapness.

Balance sheet. Long-term debt was $13,092M at year-end 2025; cash $2,883M; net debt ~$10.3B, or ~2.4x Adjusted EBITDA — down from ~4.4x in 2022. Tenet termed out its maturities in 2025 (issuing $2.25B of 2032/2033 notes to redeem the $2.25B of Feb-2027 second-lien notes); near-term maturities are light and there is no wall before 2028. Moody’s upgraded the corporate family rating to Ba2 from Ba3 (stable) in June 2026, one notch below investment grade. Liquidity is ample (~$3B cash, undrawn revolver). This is a genuinely de-risked balance sheet — the single clearest win of the transformation.

The NCI drag — the most important financial nuance. Because USPI is a web of physician joint ventures, a large minority of consolidated profit is not Tenet’s. In FY2025, minority partners captured $960M of the $2,367M consolidated net income (~40%) and were paid ~$809M of cash distributions; net income attributable to Tenet common was $1,407M, and diluted EPS $15.49. On the balance sheet, redeemable NCI (mezzanine, subject to physician put rights) was $2,956M and non-redeemable NCI $1,797M — together the ~$4.75B “wedge” that sits between enterprise value and equity. Every per-share, FCF, and EV/EBITDA judgment must use net-of-NCI figures; headline consolidated numbers flatter the common holder.

Verdict: economics do improve with scale — margins, ROIC, and leverage all moved the right way — but the quality is one notch below the headline. Peak margins, a large and growing profit claim by minority partners, and a per-share base flattered by an availability-gated buyback mean the “20%+ margin, $4.6B EBITDA” franchise is worth less to Tenet’s own shareholders than the consolidated statements suggest.

7. Capital Allocation

The scorecard: a real transformation, executed adequately rather than brilliantly. Since the ~$5B hospital-divestiture wave (FY2024 proceeds of $4,981M from selling South Carolina, Central-California, and five Alabama hospitals — the source of the one-time $2,916M gain and the un-repeatable $32.70 FY2024 GAAP EPS), Tenet has directed cash to two ends: deleveraging (the clear win) and buybacks (competent but not value-disciplined).

Deleveraging — the win. Net debt ~$14.2B → ~$10.3B; leverage ~4.4x → ~2.4x; a ratings upgrade to Ba2. Management prioritized the balance sheet first, which was the right call and is the foundation of the equity re-rating.

Buybacks — availability-gated, not valuation-disciplined. The dollar-weighting is unflattering:

Tenet bought the fewest dollars when the stock was cheapest ($250M at ~$45) and the most at the highest prices ($1.39B at ~$159), because buyback capacity was gated by the deleveraging priority, not by valuation. Every tranche is still above water versus $204 today, so it “worked” — but this is availability-driven, not the counter-cyclical discipline of a great allocator. Share count fell from ~106M (2020) to 86.95M (2025); $1.49B of authorization remained at year-end. No dividend. Capex ~$1.0B/yr.

M&A — disciplined USPI tuck-ins. The USPI platform was assembled in 2020–2021 (the two SurgCenter Development transactions, ~$1.1B each). Since then, spend has been disciplined bolt-ons: acquisitions net of cash of $308M/$571M/$224M (2025/2024/2023). No goodwill impairments have been flagged — a clean record. The rationale (shifting capital toward higher-margin, lower-capital ambulatory) is sound and consistent.

The hidden capital call — NCI buy-ups and leakage. Beyond the ~$0.8–1.0B/yr of profit distributed to minority partners, Tenet spends $92–200M/yr buying up NCI stakes (plus one-offs like the June-2022 Baylor 5% USPI buy-in for $406M, and the January-2026 redemption of CommonSpirit’s 23.8% Conifer stake for $540M). This is a real, recurring use of cash that grows as USPI grows and competes directly with every buyback and debt-paydown dollar. It is the least-appreciated feature of Tenet’s capital allocation.

Incentives — adequate structure, wrong emphasis. The annual bonus is 70% Adjusted EBITDA + 30% Adjusted FCF-less-NCI (funded at the 200% cap in FY2025); long-term incentives are 100% equity, with CEO PSUs on 50% Adjusted EPS + 50% Adjusted FCF-less-NCI and a ±25% relative-TSR modifier versus exactly three peers (CYH, HCA, UHS). There is no ROIC or return-on-capital metric anywhere — the plan rewards the size of EBITDA/EPS/FCF, not the quality of the USPI acquisitions or the buyback timing, a mild empire-building incentive. CEO Saum Sutaria’s 2025 total compensation was $43.1M (up 75%, inflated by an $18M one-time retention grant stacked on the $18M annual grant), with a new agreement guaranteeing ≥200% target bonus through 2028 and a ~$164M change-in-control acceleration. Structural governance is clean (clawbacks, anti-hedging/pledging, >93% say-on-pay, no related-party transactions, compliant ownership guidelines), but the emphasis and the max-payout year are worth flagging.

Insider behavior — uniformly distributive. Across the trailing ~2.5-year Form 4 corpus there are zero code-P open-market purchases; activity is entirely RSU/option vesting and associated sales (~482K shares sold at ~$164 average), including the CEO selling ~178,762 shares at ~$170 (~$30M). Aggregate insider ownership is <1%. The former Glenview/Larry Robbins activist stake is no longer a >5% position (top holders are all passive index funds). No one inside has bought at any price.

Verdict: capital allocation has been good on the balance sheet and adequate everywhere else. The deleveraging was excellent and value-creating; the buyback was competent but poorly dollar-weighted; the M&A is disciplined; but the growing NCI leakage, the no-ROIC incentive design, and the sold-never-bought insider record keep this from being the mark of a top-tier allocator.

8. Changes and Headwinds — Last Two Years

Strategic and structural changes.

• Leadership stability. Dr. Saum Sutaria (Chairman & CEO since 2022, architect of the ambulatory/high-acuity pivot) and CFO Sun Park remain in place — continuity of strategy, no churn.
• The hospital-divestiture program is complete. ~14 hospitals sold in 2023–24; the remaining footprint is smaller (50 hospitals, eight states), higher-margin, and funded both the deleveraging and USPI expansion.
• The Conifer transaction (2025–26). Tenet restructured the Conifer JV: it retired ~$885M of redeemable-NCI and other obligations, bought back CommonSpirit’s 23.8% equity for ~$540M, and pulled forward ~$1.9B of contract cash flows (over three years instead of six), for an estimated after-tax NPV benefit of ~$1.0–1.1B (against ~$150M of 2026 cash taxes and a one-time $40M favorable Q1’26 revenue adjustment). CommonSpirit servicing concludes at end-2026.
• Relentless USPI expansion (35 facilities added in 2025; 7 ASCs + 3 de novos in Q1’26; ~570-center network) and a ratings upgrade to Ba2 (Moody’s, June 2026).

Headwinds — the central bear case, and it is time-staggered.

• (a) ACA enhanced premium tax credit (EPTC) expiration — the 2026–27 hospital headwind. The enhanced subsidies expired at end-2025. Management models a ~20% reduction in exchange enrollment and a ~$250M FY2026 Adjusted EBITDA headwind, almost entirely in the hospital segment (only ~$30M at USPI), with higher exposure in Arizona, Michigan, and California. Exchange business is ~6% of consolidated revenue; Q1’26 same-store exchange admissions fell ~10% year-over-year, though attrition ran at roughly half the linear assumption early on (grace/effectuation periods). The real risk is 2027 — a full year of attrition plus a second round of premium hikes — not 2026.
• (b) OBBBA / 2025 reconciliation law — the 2028+ Medicaid headwind. Enacted July 2025, OBBBA caps Medicaid state-directed payments (SDPs) at 100%/110% of Medicare, phases down grandfathered SDPs by 10%/yr from 1/1/2028, and grinds the provider-tax safe harbor to 3.5% by 2032, alongside work requirements and stricter eligibility. Tenet’s supplemental Medicaid revenue is material — ~$1.34B in FY2025 (~$1.2B normalized), $304M in Q1’26 — and disproportionately hospital-segment and high-margin. This is a 2028+ structural drag, not a 2026/27 P&L event; management is pre-funding an offset via a “structural” cost/AI program built explicitly “in anticipation of… '28, '29.”
• © Other, largely benign. Labor pressure has abated (contract labor is only 2.1% of salaries/wages/benefits; payer rate increases run +3–5%; 2026 is ~high-90s% contracted). Site-neutral policy is a modest hospital-HOPD risk but a net positive for USPI. Tenet’s perennial (now contained) litigation line runs ~$50–65M/yr, a legacy of historic DOJ matters. A Section-382 ownership-change limitation on NOLs is a subtle constraint on aggressive buybacks.

Verdict: the changes strengthen the thesis (leaner, delevered, ambulatory-tilted, upgraded), but the headwinds are real and staggered. The bear case is not a single cliff — it is a ~$250M hospital hit in 2026 that worsens in 2027 (EPTC), followed by a structural Medicaid squeeze from 2028 (OBBBA). The ambulatory pivot is the explicit hedge for both, but with hospitals still 56% of EBITDA, the hedge is partial, and the out-year magnitude is genuinely unquantified.

9. Risk Analysis (Risk Matrix)

Catastrophic-loss assessment. A permanent-impairment / total-loss outcome is low-probability given the de-risked balance sheet (2.4x leverage, Ba2, no near maturities) and the genuinely good, insulated USPI franchise. The realistic severe downside is a 40–50% drawdown if peak margins meet the full policy squeeze and the multiple de-rates toward its distressed history — an amplified but survivable air-pocket, not an existential event.

10. Valuation Discussion (Embedded Expectations)

Where THC trades. At $203.72, market capitalization is ~$17.7B; adding net debt (~$10.3B) and the NCI wedge (~$4.75B) gives an enterprise value of ~$32–33B. Against TTM EBITDA of ~$4.72B (or the FY2026 guide midpoint of ~$4.635B) that is ~6.8–7.0x EV/EBITDA; against forward adjusted EPS of ~$17.53 it is ~11–12x; against FY2025 GAAP diluted EPS ($15.49) ~13x. Consolidated FCF yield is ~14%, but the net-of-NCI FCF yield that accrues to Tenet holders is closer to ~10% (~$1.8B / $17.7B).

Peer comparison.

*CYH is a distressed stub, not quality-comparable. THC’s ~2-turn EV/EBITDA discount to HCA is deserved on quality (roughly half HCA’s ROIC) — but the gap has narrowed as Tenet’s margins converged toward HCA’s, and the pure-ASC comp (SGRY at ~11–13x) is the reason a sum-of-the-parts argues USPI is worth well more than the blended multiple implies.

The own-history tell. On AZI’s ten-year own-history percentiles, THC screens cheap on book (P/B 16th), mid-range on earnings (P/E ~45th), and richest-ever on sales (P/S 94.6th) — composite ~52nd. That split is the thesis in one line: the stock looks cheap on earnings only because margins are at record highs, and the price-to-sales percentile warns there is little cushion if those margins mean-revert. You are paying a peak-margin price on the revenue base.

Sum-of-the-parts. Valuing each segment and applying Tenet’s ownership is the cleanest frame:

• USPI: $2,026M Adjusted EBITDA × ~11x (a discount to SGRY’s ~11–13x for a higher-quality operator) = ~$22B gross EV; at Tenet’s ~60% economic ownership, ~$13.4B attributable.
• Hospital + Conifer: $2,540M Adjusted EBITDA × ~5.5x (below HCA’s ~8.6x for lower quality and policy exposure) = ~$14.0B (largely wholly owned).
• Attributable EV ~$27.4B, less net debt ~$10.3B ⇒ equity ~$17.1B ~ $197/share — essentially at the current price. Flexing the multiples (USPI 10–13x, hospital 5–6x) spans ~$150 to ~$260. SOTP says fair-to-slightly-cheap, not a bargain — and confirms that most of the value now sits in USPI, net of the physician partners’ claim.

Embedded-expectations / reverse-DCF. At ~6.8–7.0x forward EV/EBITDA on ~$2.5B consolidated FCF (~$1.8B net of NCI), a reverse-DCF (WACC ~8.5–9%) implies the market is underwriting ~mid-single-digit forward EBITDA/FCF growth — i.e., continuation of the USPI-led compounding, not zero. This is the key contrast with HCA, whose ~8.6x multiple embeds only ~0–1.5% perpetual growth (a permanent-impairment fear). THC is cheaper on the multiple but richer on the expectation: the market has already given it credit for the USPI story continuing, so the re-rating is closer to done than HCA’s. Because ~$15B of net debt + NCI sits between EV and equity, the equity is highly geared — one turn of EV/EBITDA is worth roughly ±$50/share.

What the market is pricing correctly vs. incorrectly. Correctly: the balance-sheet repair, USPI’s structural quality, and the deserved discount to HCA on ROIC. Potentially incorrectly (in either direction): whether ~20%+ blended margins are durable through the 2026–28 policy transition, and whether the physician-NCI leakage is properly reflected in the per-share math. No price target. No recommendation.

11. Variant Perception

Consensus (mildly bullish). The sell-side is constructive (TD Cowen Buy, PT $233; Cantor Overweight, PT $245): USPI is a secular ambulatory-shift winner, hospital margins have durably reset higher, deleveraging de-risked the equity (Moody’s Ba2), and policy headwinds are “manageable.” The narrative is “a transformed, higher-quality Tenet that still trades two turns below HCA.”

The strongest bull case. The mix shift to high-margin, capital-light ASCs is structural and ongoing; USPI deserves an SGRY-like double-digit multiple that the blended ~7x does not reflect; continued margin expansion plus buyback plus deleveraging compounds equity value even at a flat blended multiple; and a re-rate toward HCA parity (~8.6x) is plausible if policy proves absorbable. In a bull outcome, FY2027 Adjusted EBITDA of ~$5.2–5.4B at ~7.5–8.0x implies ~$290–320/share (+40%+).

The strongest bear case. The P/S-94.6th-percentile tell is the whole argument: you are paying a record price-to-sales on record, policy-exposed margins. EPTC expiration raises the uninsured/self-pay mix into 2027; OBBBA caps hit the hospital segment’s ~$1.2B supplemental-Medicaid stream from 2028. If margins mean-revert even 150–200bp and the multiple de-rates from ~7x back toward its ~4–5x history, the equity halves (FY2027 EBITDA ~$4.2–4.4B × ~5.25–5.5x ⇒ ~$100–120/share). Layer on ~40% of profit leaking to minority partners, a no-ROIC incentive plan, and insiders selling into the entire run-up, and the “easy money” is behind it.

The 3–5 assumptions that matter most. (1) USPI same-facility volume/case growth stays healthy (double-digit acuity-led revenue); (2) hospital EBITDA margin holds ~near 20% through the EPTC/OBBBA transition; (3) the ~$4.75B NCI doesn’t dilute the equity claim faster than USPI grows; (4) net leverage stays ~2.4x, preserving buyback capacity; (5) the multiple holds ~7x rather than reverting toward the distressed past.

Falsification tests. The bull thesis dies if: two consecutive quarters of USPI same-facility case deceleration, or hospital EBITDA margin compressing >150bp on rising uninsured mix. The bear thesis dies if: THC prints another beat-and-raise with USPI double-digit and margins flat-to-up through the first post-EPTC quarters, confirming policy is absorbed.

Factor-positioning read . THC is ~87% idiosyncratic, low-beta (~0.7 model / ~0.9 realized), and NOT a crowded factor trade — its only meaningful factor loadings are Market and a spurious DividendYield tilt (it pays no dividend), with no Momentum, Growth, or Quality loading. The related-stock cluster is an incoherent grab-bag, confirming there is no tight factor comp — the stock trades on its own fundamentals. Its risk-adjusted record is strong on three years (y3 +34%/yr, Sharpe 0.80) but has flattened recently (m6 −9.8%/yr annualized, y1 +7.8%) — the re-rating engine that drove the Sharpe is cooling. Positioning-wise, consensus is mildly offsides bullish on continuation: the market prices USPI to keep compounding at record margins, which is exactly the assumption the policy transition will test. Because the profile is idiosyncratic and non-momentum, any disappointment de-rates this stock specifically rather than being cushioned by a factor tailwind — but equally, the June–July bounce shows the same idiosyncrasy cuts both ways on the upside.

12. Fact vs. Interpretation

13. Open Questions

1. What is the precise size of Tenet’s ACA-exchange revenue and admissions exposure? The 10-K embeds it in the “managed care” line; management says ~6% of consolidated revenue, but the discrete hospital-segment exposure by state (AZ/MI/CA) is not disclosed. This is the single most important unquantified 2026–27 number.
2. What is the out-year (2028+) OBBBA Medicaid impact? Management has declined to quantify the hit to its ~$1.2B supplemental-Medicaid stream. Directionally negative and hospital-concentrated; magnitude unknown.
3. How durable is the 2026 “structural” cost/AI program that underpins the ~10% core EBITDA growth? Analysts pressed this repeatedly; management would not confirm repeatability into 2027+.
4. Does Glenview retain a sub-5% position? No longer a >5% holder in the proxy; a 13F check would confirm whether any activist pressure remains.
5. At what pace does NCI leakage grow relative to USPI EBITDA? If USPI compounds but physician ownership expands, the attributable growth to Tenet holders could lag the consolidated figure.
6. Will site-neutral / inpatient-only-list changes be a net positive (USPI) or negative (hospital HOPD) on balance? Management is positive; the regulatory detail is not yet final.

14. What Must Be True

For the bull case to work (upside toward ~$290–320):

• USPI continues to compound Adjusted EBITDA at low-double-digits (organic acuity mix-up + disciplined M&A), and hospital margins hold ~near 20% through the EPTC/OBBBA transition, taking FY2027 consolidated Adjusted EBITDA to ~$5.2–5.4B.
• The market re-rates the blend toward HCA parity (~8x) as policy proves absorbable and the ASC half is recognized.
• Falsification test: two consecutive quarters of USPI same-facility case deceleration, or hospital EBITDA margin compressing >150bp on rising uninsured mix, or FY2027 EBITDA guided down — any of which breaks the “compounding continues” premise the multiple requires.

For the bear case to work (downside toward ~$100–120):

• EPTC attrition and the OBBBA Medicaid caps compress hospital revenue and mix; blended margins mean-revert 150–200bp from record highs; and the multiple de-rates from ~7x back toward its ~5x history as growth stalls.
• NCI leakage grows faster than attributable USPI earnings, so per-share value stagnates even if consolidated EBITDA holds.
• Falsification test: a beat-and-raise quarter with USPI same-facility revenue still double-digit and hospital margins flat-to-up through the first post-EPTC quarters — confirming the policy shock is a manageable air-pocket, not a step-down.

The swing variable: the FY2027 hospital-margin trajectory through the EPTC transition. If margins hold, the bull’s “compounding continues” story survives and the multiple is defensible; if they crack, both earnings and the multiple de-rate together, and the leverage-plus-NCI gearing amplifies the equity move to the downside.

15. Source Appendix

Primary and quantitative sources (full detail in the separate Source Appendix, Appendix B):

• SEC filings: Tenet Healthcare FY2025 Form 10-K (filed 2026-02-17); Q1 2026 Form 10-Q and earnings 8-K; FY2021–2024 10-Ks; DEF 14A proxy (2026-04-16); Form 3/4/5 corpus (2024–2026) — all mirrored locally from EDGAR (CIK 0000070318).
• Earnings-call transcripts: Q4 2025 (2026-02-11), Q1 2026 (2026-04-30), Q3 2025 (2025-10-28) — via ROIC.ai.
• Quantitative: ROIC.ai (financial statements, ratios, enterprise value, per-share, valuation multiples); AZI valuation-index own-history percentiles and 5-year price series; FactorsToday factor loadings, leaderboard, and stock-info.
• Industry/policy: Becker’s ASC (top ASC operators 2025); GMInsights (US ASC market); KFF (2026 ACA marketplace); HFMA and National Health Law Program (OBBBA SDP/provider-tax mechanics); Moody’s (June 2026 upgrade).
• Peer comparison: HCA Healthcare public filings for hospital-industry framing and comps.
• Context (labeled, dated): industry/expert commentary circa 2020 on Tenet’s ambulatory positioning (framework only, not current data).

Management commentary throughout is treated as a hypothesis validated against filings, financials, and external data. All non-obvious facts are cited with source and date in Appendix B.

APPENDIX A — Standard Diligence Questionnaire

Tenet Healthcare Corporation (NYSE: THC) · 2026-07-02

Supplemental to the research memo. Fact / Interpretation / Assumption labeled where it matters. Where a question does not map to Tenet’s model, the correct sector analog is given.

General

What thoughtful questions have other investors asked about this company? The recurring institutional debates are: (1) Is USPI a hidden compounder that deserves a pure-ASC (SGRY-like) multiple, or is the sum-of-the-parts already reflected in the ~7x blended EV/EBITDA? (2) How much of the record 21%+ EBITDA margin is durable versus a peak that policy (EPTC/OBBBA) will unwind? (3) How should one adjust for the ~40% of consolidated profit that leaks to USPI’s physician minority partners? (4) Is the re-rating from ~4x to ~7x EV/EBITDA “done,” so future returns depend on earnings compounding rather than multiple expansion? (5) Why have insiders sold — never bought — into the entire five-year run-up, and why is there no ROIC metric in the comp plan?

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: at a structural/cyclical high on margin. Blended EBITDA margin (21.4%) and hospital margin (15.7%) are both at record levels, achieved through divestitures, acuity mix-up, and cost discipline; the AZI P/S percentile (94.6th, richest-ever) corroborates peak profitability. Volumes, by contrast, are mid-cycle (hospital admissions flat; USPI cases +0.3% same-facility).

Driven by the external environment or internal actions? Primarily internal (portfolio reshaping, USPI mix shift, deleveraging), with an external tailwind (secular inpatient-to-outpatient migration) and looming external headwinds (ACA EPTC expiry, OBBBA Medicaid caps).

How stable are revenues? Demand is defensive and demographic; the sensitivity is in payer mix, not volume — a coverage shock (EPTC) moves insured patients to uninsured/Medicaid without necessarily reducing the caseload, compressing revenue and margin.

Outlook for products/services; how big is the market? ASC market ~$40B, growing ~3.5–6%/yr (secular, USPI is #1). Hospital market mature, low-growth, policy-exposed. Both domestic (USPI 37 states, hospitals 8 states); no material international.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Hospitals: consolidating but structurally average. ASCs: more competitive — payer-owned Optum/SCA and PE capital are flooding in, pressuring JV and acquisition economics (Marathon capital-cycle warning).

How profitable is the business (ROIC, ROE)? ROIC ~13–15% (above the ~8–9% WACC, below HCA’s ~20%). ROE and P/B are not usable — negative tangible book (~−$40/share) from goodwill-funded USPI M&A and buybacks. Use ROIC and net-of-NCI economics.

How profitable is the industry; barriers to entry? Hospitals: middling returns, high barriers (CON, capital intensity) but tax-advantaged not-for-profit competition. ASCs: high returns, moderate barriers (CON in ~40% of USPI states, physician relationships, scale), eroding as capital enters.

Can the business be easily understood? Mostly — but the NCI/JV structure and the segment-vs-consolidated Adjusted-EBITDA definitions require care; headline consolidated figures overstate the common holder’s claim.

Can it be undermined by foreign low-cost labor? No — care delivery is local and licensed.

Do brands matter? Modestly. Local hospital reputation and physician relationships matter more than a corporate brand; USPI’s edge is physician-owner alignment and scale, not brand.

Nature of competition; customers’ switching costs? Competition is local and service-line-specific (hospitals) and physician-JV-driven (USPI). Switching costs are real in USPI (surgeon equity ownership locks in case volume) and modest in hospitals (local density, referral patterns).

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? USPI’s franchise value and physician-JV relationships are carried largely as goodwill/intangibles; the economic value of the #1 ASC platform arguably exceeds book. Conversely, the redeemable-NCI put obligations ($2,956M mezzanine) are a real claim.

Off-balance-sheet liabilities? Operating leases (capitalized under current GAAP); redeemable NCI puts are on the balance sheet in mezzanine. Perennial (contained) litigation contingencies. Section-382 NOL limitation risk from buybacks/5%-holder trading.

How conservative is the accounting? Reasonable. FY2025 OCF ($3,540M) exceeded net income ($2,367M) — clean conversion, no aggressive revenue/gain reliance. Caveat: FY2024 GAAP EPS ($32.70) is inflated by ~$2.9B one-time divestiture gains and must be normalized.

How CapEx-hungry is the business? Moderate — ~$1.0B/yr, ~4.7% of revenue. USPI is capital-light (ASCs are cheap to build/buy); hospitals are the capital-heavy half, which Tenet has been shrinking.

Capital Allocation & Management

How much FCF, and how is it used? Consolidated FCF ~$2.5B; net-of-NCI FCF ~$1.8B (the figure that accrues to Tenet holders). Uses: deleveraging (the win), buybacks (competent but poorly dollar-weighted), USPI tuck-ins (~$250–350M/yr), and NCI buy-ups (~$92–200M/yr). No dividend.

Significant acquisitions recently? USPI platform built 2020–21 (two ~$1.1B SurgCenter deals); since then disciplined bolt-ons ($308M in 2025). No goodwill impairments.

Buying back shares? Yes — 106M (2020) → 86.95M (2025) shares, ~8.6% retired in 2025 alone; $1.49B authorization remaining. But the buyback spent the most dollars at the highest prices (availability-gated by deleveraging, not valuation-disciplined).

Issuing shares to insiders? RSU/PSU grants are the sole LTI vehicle; dilution is offset by buybacks. CEO 2025 total comp $43.1M (inflated by an $18M one-time grant).

Compensation policy / motivations of management? Bonus 70% Adjusted EBITDA + 30% Adjusted FCF-less-NCI; PSUs 50% Adjusted EPS + 50% Adjusted FCF-less-NCI + ±25% rTSR vs. CYH/HCA/UHS. No ROIC metric — rewards size, not capital quality (mild empire-building incentive). Structurally clean governance, but a max-payout year and ~$164M CIC are flags.

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — ordinary NYSE-listed C-corp common stock; standard 1099 reporting.

Dividend policy? None. Capital return is via buyback only.

How profitable is the business? EBITDA margin 21.4% (segment); ROIC ~13–15%. Profitable and improving, but at peak margins and with ~40% of consolidated profit accruing to minority partners.

Is net income diverging from cash from operations? No divergence in 2025 (OCF > NI). The relevant adjustment is NCI (consolidated NI $2,367M vs. Tenet-common $1,407M), not an accrual/cash gap.

Risks & Downside

What factors would cause the stock to decline? Margin mean-reversion from record highs; the staggered policy squeeze (EPTC 2026–27, OBBBA 2028+); a multiple de-rate from ~7x toward its distressed history; USPI case deceleration or intensifying ASC competition; growing NCI leakage.

Risk of catastrophic loss? Low. The balance sheet is de-risked (2.4x leverage, Ba2, no maturity wall before 2028) and USPI is a genuinely good, insulated franchise. The realistic severe case is a 40–50% drawdown (policy + margin + multiple), not a total loss.

Chance of a total loss? Very low, absent a simultaneous policy shock, margin collapse, and refinancing stress that the current structure makes remote.

Recent News & Events

Has the business environment changed recently? Yes — two 2025 policy shocks (ACA EPTC expiry end-2025; OBBBA enacted July 2025) reframed the bear case, and the stock round-tripped a ~34% policy-scare drawdown before recovering on a Q1’26 beat, a raised EPS view, and a Moody’s upgrade. Today (2026-07-02) the stock rose ~8.5% on a Cantor Overweight/$245 note and an acuity survey — analyst-driven, not a policy change.

Significant acquisitions / divestitures? Hospital-divestiture program (~14 hospitals, ~$5B) completed 2023–24; continuous USPI tuck-ins; the Conifer JV restructuring (bought back CommonSpirit’s 23.8% for ~$540M, pulled forward ~$1.9B of contract cash), effective January 1, 2026.

Change in accounting policies? None material. Segment reporting is now two segments (Hospital Operations, Ambulatory Care), both managed to Adjusted EBITDA.

Recent changes — new markets, facilities, management? Leadership stable (Sutaria CEO since 2022, Park CFO). One greenfield hospital opened (Florida Coast Medical Center, 54-bed, Sept 2025); ~35 USPI facilities added in 2025; ratings upgrade to Ba2 (June 2026).

APPENDIX B — Source Appendix

Tenet Healthcare Corporation (NYSE: THC) · Research date 2026-07-02

Primary sources first; management commentary treated as hypothesis and validated against filings, financials, and external data. All figures reconciled to primary filings where a primary source exists (EDGAR, CIK 0000070318).

1. SEC filings (primary; mirrored locally from EDGAR)

Key reconciled figures (FY2025 10-K unless noted): revenue $21,310M; segment Adjusted EBITDA $4,566M (Hospital $2,540M / USPI $2,026M); GAAP diluted EPS $15.49; net income to Tenet common $1,407M vs. consolidated $2,367M; NCI to minorities $960M; redeemable NCI $2,956M + non-redeemable NCI $1,797M; long-term debt $13,092M; cash $2,883M; net debt ~$10.3B; OCF $3,540M; capex ~$1,010M; shares outstanding 86.95M; hospital payer mix (net patient service revenue $13,942M) managed care 69.5% / Medicare 15.2% / Medicaid 10.9% / uninsured 0.4%.

2. Earnings-call transcripts (via ROIC.ai)

3. Quantitative data services

• ROIC.ai — income statement, balance sheet, cash flow, profitability/valuation ratios, enterprise value, per-share data (multi-year). Enterprise value ~$31–33B; TTM EBITDA ~$4,719M; EV/EBITDA ~6.6–7.0x; ROIC ~13.25% (FY2025). Third-party aggregated; reconciled to filings — filing figures govern where they differ.
• AZI valuation-index (own 10-year history percentiles) — composite 51.8th; P/E 44.9th; P/B 15.9th; P/S 94.6th (richest-ever); latest price $203.72, TTM EPS $19.23. AZI 5-year daily price series (adjusted OHLCV, EMAs) — five-year low $37.50 (2022-10-21), all-time high $244.80 (2026-03-04).
• FactorsToday — factor loadings (Market β ~0.69–0.72; spurious DividendYield +0.15; R² ~12–13% ⇒ ~87% idiosyncratic; no Momentum/Growth/Quality); leaderboard (y3 +34%/yr, Sharpe 0.80; m6 −9.8%/yr; lifetime max drawdown −89.5%); stock-info (beta 0.92 realized, alpha +0.19, rs_peak −16.78).

4. Industry, policy, and analyst sources (public)

5. Peer comparison (public filings)

• Comparative analysis of HCA Healthcare — hospital-industry structure, payer-mix mechanics, EPTC/OBBBA policy framing, and comps (HCA ~8.6x EV/EBITDA, ~12.5x forward P/E, ~20% ROIC), drawn from HCA’s public filings.

6. Context source (labeled; dated)

• Industry/expert commentary on Tenet’s ambulatory positioning vs. HCA and the outpatient mix-shift (circa 2020) — dated; treated as framework, not current data.

Note on non-primary data: ROIC.ai, AZI, and FactorsToday are third-party aggregators used for speed and cross-checking; every material figure driving a verdict is reconciled to the underlying SEC filing, which governs in case of conflict. No third-party analyst price target is adopted as a Tenet valuation; the only position/valuation view in this report is the labeled Author’s Take.